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See related article on page 551. The most important factor predicting the outcome for patients withlung cancer (and indeed most solid tumors) is whether the tumor hasspread locally, regionally, and/or systemically. It is well recognizedthat occult spread of tumor can occur, even in patients who haveundergone complete removal of the primary tumor, and this phe-nomenon is the basis for the later development of overt metastases in
these patients. Indeed, the possible presence of occult tumor dissemination is the
rationale behind the use of systemic adjuvant chemotherapy in patients who have
undergone definitive treatment of the primary tumor. Recognizing this, substantial
efforts have been made to devise sensitive methods to detect occult regional and
systemic spread of tumor. The central idea is that the detection of occult tumor
might identify those patients at increased risk for recurrence and might thus affect
the subsequent management of these patients, including the decision to administer
adjuvant systemic therapy.
The article by Marchevsky and colleagues1 comes from a group long involved in
the study and analysis of lung cancer and represents a substantial undertaking. The
goal of this study was to determine the incidence and significance of finding
previously undetected lymph node metastases (termed here “occult lymph node
metastases”) in patients with non–small cell lung carcinoma by using sensitive
immunohistochemical procedures. The investigators examined a range of patients
with non–small cell lung carcinoma, including those with node-negative (N0), N1,
and N2 disease.
In the case of patients with N2 disease, no further metastases were detected by
means of immunohistochemistry in lymph nodes, indicating that ultrasensitive
detection methods might not provide useful additional information in these patients.
In patients with N1 disease, 9 of 11 patients had tumor cells detected by means of
immunohistochemistry, but none of these patients were upstaged to N2 disease. The
authors suggest that detection of occult metastases with sensitive methodologies
might not be useful in patients with node-positive lung cancer. This is perhaps not
entirely surprising. Patients with node-positive lung cancer generally have a poor
outcome, and detection of further occult disease might not be expected to have a
major effect on the management of these patients.
This study also suggests that patients with occult lymph node metastases or those
with microscopic lymph node involvement (as defined by tumor size in the lymph
node of 2 mm [Nmi]) might have better outcomes than patients with overt N1 or
N2 disease, the implication being that minimal lymph node involvement might
identify a prognostically different subgroup of patients than those with overt lymph
node involvement. This is an interesting and important notion and again is entirely
expected because the extent of tumor involvement is well known to have a major
effect on outcome. For example, in patients with lung cancer, those with N2 disease
clearly do more poorly than those with N1 disease. In the case of breast carcinoma,
it has been well documented that the number of involved axillary nodes is a highly
significant predictor of outcome; patients with fewer positive nodes do far better
than those with larger numbers of positive nodes.2,3 Thus we might expect that if the
presence of minimal lymph node involvement (including occult metastases) is
prognostically important, the effect on outcome might be less than for patients with
a greater tumor burden (eg, more obvious involvement determined by using routine
histology).
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If detection of occult metastasis has an effect on out-
come, it might be expected to be most important in patients
with node-negative (N0) disease. In this study 33 patients
were initially classified as node negative, and a substantial
minority (5 [15%]) of these patients had occult metastasis
detected by means of immunohistochemistry. These results
are entirely consistent with other studies, and once again
demonstrate that a proportion of patients with histologic
node-negative disease will have tumor cells detected in their
lymph nodes by means of more sensitive methods.4,5
The larger issue is the effect of occult metastases on
outcome. In the present study1 the presence of occult lymph
node metastases was not statistically significantly associated
with a survival difference compared with cases that re-
mained node negative after immunohistochemistry. How-
ever, this should not be interpreted to mean that the presence
of occult lymph node metastases is not important. The
number of node-negative patients in the present study was
too small to have the power to draw conclusions, regarding
the prognostic significance of occult lymph node metasta-
ses. Cohort size has been an issue with studies of occult
lymph node metastases in a number of tumor systems,
notably breast, lung, and colon cancer.4,6,7 Thus no conclu-
sions should be drawn from the present study regarding the
prognostic significance of occult metastases in patients with
node-negative disease.
Several other studies with large numbers of patients have
indicated that the presence of occult lymph node metastases
in patients with node-negative lung cancer is a highly sig-
nificant predictor of recurrence and survival,4,5,8 and the
same is true for patients with other tumors as well.6,7,9 In
fact, the accumulating evidence is that occult regional
(lymph node) metastasis might indeed be prognostically
important in patients with node-negative lung cancer, node-
negative breast cancer, and other tumors.4,6,9
Although the present study1 is focused on the detection
of occult regional (lymph node) metastases, there exist
substantial efforts to detect occult systemic dissemination of
tumor cells as well, through the testing of bone marrow and
blood. These studies also indicate that the presence of occult
tumor cells in the bone marrow identifies patients with lung,
breast, and other tumors, who are at significantly increased
risk for progression.4,6,9-13
The detection of occult metastases might help us to better
identify patients with lung (and other) cancer who are at
higher risk for development of metastatic disease and who
would thus most benefit from systemic adjuvant therapy.
Importantly, sensitive techniques to determine those pa-
tients who do and do not have detectable occult metastases
might also identify patients with a highly favorable prog-
nosis, who might thus not benefit from systemic treatment
and for whom systemic treatment will only incur expense
and side effects.
However, as pointed out by the present study,1 the utility
and significance of detecting occult tumor cell dissemina-
tion remains controversial. To resolve these issues, the
American College of Surgeons Oncology Group has insti-
tuted 2 large clinical trials. The Z40 trial in lung cancer and
the Z10 trial in breast cancer will examine bone marrows
and lymph nodes for the presence of occult metastases.
These studies currently involve over 120 institutions, with
expected accrual of over 1200 patients to the Z40 lung
cancer study and over 3000 patients to the Z10 breast cancer
study. If the clinical utility of the detection of occult me-
tastases is confirmed by these large-scale multi-institutional
clinical trials, it will have an important effect on the future
management of lung cancer and other malignancies.
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